New drug shows promise in reducing painful sickle cell crises

NCT ID NCT04662931

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 38 times

Summary

This study looked at the safety of a drug called crizanlizumab in 140 Indian patients aged 16 and older with sickle cell disease who have had painful crises. The drug is meant to reduce the frequency of these crises. Researchers monitored serious side effects and other adverse events to ensure the treatment is safe for this population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE (SCD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Guwahati, Assam, 781003, India

  • Novartis Investigative Site

    Raipur, Chhattisgarh, 492099, India

  • Novartis Investigative Site

    Kozhikode, Kerala, 673008, India

  • Novartis Investigative Site

    Bhubaneswar, Odisha, 751003, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500082, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700014, India

Conditions

Explore the condition pages connected to this study.